Compare · ABT vs MDXG
ABT vs MDXG
Side-by-side comparison of Abbott Laboratories (ABT) and MiMedx Group Inc (MDXG): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ABT and MDXG operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- ABT is the larger of the two at $175.37B, about 273.8x MDXG ($640.5M).
- Over the past year, ABT is down 18.6% and MDXG is down 32.8% - ABT leads by 14.2 points.
- ABT has been more active in the news (12 items in the past 4 weeks vs 2 for MDXG).
- ABT has more recent analyst coverage (25 ratings vs 7 for MDXG).
- Company
- Abbott Laboratories
- MiMedx Group Inc
- Price
- $100.68+1.91%
- $4.31-2.82%
- Market cap
- $175.37B
- $640.5M
- 1M return
- +11.09%
- +16.80%
- 1Y return
- -18.60%
- -32.76%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- News (4w)
- 12
- 2
- Recent ratings
- 25
- 7
Abbott Laboratories
Abbott Laboratories discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. The Diagnostic Products segment offers laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and measure infectious agents; point of care systems; cartridges for testing blood; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The Nutritional Products segment provides pediatric and adult nutritional products. The Medical Devices segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; and diabetes care products, as well as neuromodulation devices for the management of chronic pain and movement disorders. The company was founded in 1888 and is based in North Chicago, Illinois.
MiMedx Group Inc
MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts. The company's patented and proprietary processing method employs aseptic processing techniques in addition to terminal sterilization. Its products include EpiFix, a semi-permeable protective barrier membrane product used for the treatment of chronic wounds, including diabetic foot ulcers, venous leg ulcers, pressure ulcers, and burns; AmnioFix, a semi-permeable protective barrier membrane product for the treatment of wounds related to surgical procedures; EpiCord and AmnioCord that are dehydrated human umbilical cord allografts intended for homologous applications; and AmnioFill that consists of particles of connective tissue matrix derived from placental disc and placental membranes. The company's products have applications primarily in the areas of wound care, burn, surgical, and non-operative sports medicine sectors of healthcare. It also sells allografts for dental applications on an original equipment manufacturer basis. The company sells its products through direct sales force and independent sales agents, as well as through independent distributors primarily in the United States. MiMedx Group, Inc. is headquartered in Marietta, Georgia.
Latest ABT
- Abbott Laboratories filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Abbott Reports Second-Quarter 2026 Results and Raises Full-Year EPS Guidance
- SEC Form 4 filed by Director Stratton John G
- SEC Form 4 filed by Director Roman Michael F
- SEC Form 4 filed by Director Gonzalez Patricia Paola
- SEC Form 4 filed by Director Conroy Kevin T
- SEC Form 4 filed by Director Ahuja Nita
- EXECUTIVE VICE PRESIDENT Morrone Louis H. covered exercise/tax liability with 269 units of Common shares without par value, decreasing direct ownership by 0.35% to 76,574 units (SEC Form 4)
- Robert W. Baird initiated coverage on Abbott Labs with a new price target
- EVP, GC AND SECRETARY Cushman Elizabeth C. covered exercise/tax liability with 560 units of Common shares without par value, decreasing direct ownership by 1% to 38,013 units (SEC Form 4)
Latest MDXG
- Chief Financial Officer Doug Rice covered exercise/tax liability with 12,749 shares, decreasing direct ownership by 3% to 399,566 units (SEC Form 4)
- Chief Commercial Officer Maersk-Moller Kimberly covered exercise/tax liability with 19,820 shares, decreasing direct ownership by 6% to 309,630 units (SEC Form 4) (withholding tax)
- MiMedx Group Inc filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders
- The Quiet Revolution in Regenerative Medicine: From Replacing Tissue to Rebuilding It
- Director Bierman James L was granted 50,913 shares, increasing direct ownership by 24% to 263,684 units (SEC Form 4)
- Director Puhy Dorothy E was granted 50,913 shares, increasing direct ownership by 88% to 108,510 units (SEC Form 4)
- Director Newton Todd was granted 50,913 shares, increasing direct ownership by 12% to 463,684 units (SEC Form 4)
- Director Hawkins William A was granted 50,913 shares, increasing direct ownership by 25% to 254,931 units (SEC Form 4)
- Director Olson Tiffany was granted 50,913 shares, increasing direct ownership by 88% to 108,510 units (SEC Form 4)
- A Fresh FDA Catalyst Is Putting Regenerative Wound Care in Focus